News | October 06, 2014

St. Vincent is Second in the Nation to Implant New Investigational HeartMate III VAD

St. Vincent Implant Thoratec Corp. HeartMate III VAD

October 6, 2014 — St. Vincent Heart Center officials announced that the faith-based hospital is the second in the nation to implant the new investigational “heart pump.” Christopher Salerno, cardiothoracic surgeon at St.Vincent Heart Center implanted the new Left Ventricular Assist System (LVAS) called the HeartMate III on a 19-year-old patient.  St. Vincent Heart Center is participating in the U.S. Investigational Device Exemption (IDE) clinical trial with the HeartMate III for patients with congestive heart failure. The Thoratec HeartMate III Left Ventricular Assist Device (LVAD) is a new advancement in mechanical circulatory support (MCS). St. Vincent Heart Center is part of St. Louis-based Ascension Health.

Lucas Jackson, 19, of North Vernon, Ind., was diagnosed with hypertrophic cardiomyopathy — a disease in which the heart muscle becomes abnormally thick, making it harder for the heart to pump blood — and congestive heart failure days after his 18th birthday. Nine months earlier, his father passed away from the same condition. Prior to his father’s passing and his diagnosis, Jackson was your typical teenager with a passion for dirt track car racing. The oldest of four, he is one of three siblings who have a genetic heart condition. Jackson received the new HeartMate III LVAD while he waits for a new heart.

The HeartMate III LVAD is a small implantable mechanical device that helps circulate blood throughout the body. Sometimes called a “heart pump” or “VAD,” it is designed to supplement the heart’s pumping function for patients whose hearts are too weak to adequately pump blood on their own. The fully magnetically levitated technology foundation is designed to lower adverse event rates through improved compatibility with blood, while HeartMate III also enhances ease of surgical placement through its compact size.

Compared to other LVADs on the market, the HeartMate III has been designed to be more patient friendly. The battery has a longer run time — thus far testing shows 17 hours on a pair of batteries. Also, the smaller device allows for a less invasive surgery. Some of the benefits of this new device are that there is no pump pocket required below the diaphragm thus potential for less dissection, shorter surgery time, and less bleeding.

“While the number of patients being diagnosed with advance heart failure continues to rise, the number of donor hearts has remained stagnant,” said Salerno. “St. Vincent Heart Center is proud to be one of the first to assess this therapy and look forward to making it available to patients in Indiana.”

More than 5 million people in the United States are afflicted with congestive heart failure (CHF). Of these, more than 250,000 are advanced cases, with an annual mortality rate of 80 percent.

The HeartMate III LVAS U.S. IDE Clinical Trial is designed to evaluate the safety and effectiveness of the investigational device. Patients who agree to participate in the study are randomly assigned to receive either the HeartMate II or the HeartMate III LVAD.

For more information:

Related Content

FDA Class I Recall Issued for Medtronic HeartWare HVAD Pump
News | Ventricular Assist Devices (VAD) | May 29, 2020
May 29, 2020 — Medtronic is recalling its HeartWare HVAD...
Abiomed Receives FDA PMA Approval for Impella 5.5 With SmartAssist
Technology | Ventricular Assist Devices (VAD) | September 27, 2019
Abiomed’s newest heart pump, the Impella 5.5 with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre...
CorWave Presents First Successful In Vivo 60-day Study of Neptune LVAD
News | Ventricular Assist Devices (VAD) | September 12, 2019
CorWave announced successful completion of its first 60-day preclinical study to evaluate its Neptune left ventricular...
Experts Caution Against Catch-all Assumptions About LVADs and Mitral Regurgitation

Paul Tang, M.D., Ph.D., a cardiac surgeon at Michigan Medicine’s Frankel Cardiovascular Center in the OR. Image courtesy of Michigan Medicine.

News | Ventricular Assist Devices (VAD) | August 20, 2019
Left ventricular assist devices (LVADs) have been shown to help leaky mitral valves that create significant...
FDA Confirms Impella RP is Safe and Effective
News | Ventricular Assist Devices (VAD) | June 12, 2019
 In a letter sent to healthcare providers, the U.S. Food and Drug Administration (FDA) validates that Abiomed’s Impella...
Impella SmartAssist Platform Launches at SCAI
News | Ventricular Assist Devices (VAD) | May 22, 2019
Abiomed announced that the Impella CP with SmartAssist will be commercially available beginning at the 2019 Society for...
FDA Approves Impella 5.0 and Impella LD Extended Duration of Use
Technology | Ventricular Assist Devices (VAD) | May 14, 2019
The U.S. Food and Drug Administration (FDA) has approved the expansion of Abiomed’s Impella 5.0 and Impella LD...
FDA Approves Initiation of STEMI DTU Pivotal Randomized Controlled Trial
News | Ventricular Assist Devices (VAD) | May 02, 2019
Abiomed announced that, on April 26, the U.S. Food and Drug Administration (FDA) approved initiation of the ST-...
Cardiogenic Shock Survival Rates Improve in Three Years Since Impella FDA Approval
News | Ventricular Assist Devices (VAD) | April 05, 2019
Three years ago this week, Abiomed's Impella heart pump received U.S. Food and Drug Administration (FDA) premarket...